Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Teva Pharmaceuticals (TEVA) resolving all patent ...
Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was up as much as 5.6% earlier in the day. The jump comes as the S&P 500 ...
Axsome resolved litigation with a rival pharmaceutical company, protecting one of Axsome's key drugs. The settlement protects Axsome's revenue stream for more than a decade. Axsome, maker of the ...
Axsome Therapeutics, Inc. NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has received a consensus rating of “Buy” from the sixteen ratings firms that are covering the stock, MarketBeat.com reports.
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $143. ...
Analysts across Wall Street raised their price targets for Axsome. The upgrades came after news broke that the company had settled a key lawsuit. A senior analyst at the Japanese banking giant ...
Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results